Extension of the randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.
- Conditions
- Atrial fibrillationsupraventricular tachycardia10007521
- Registration Number
- NL-OMON49415
- Lead Sponsor
- Acesion Pharma ApS
- Brief Summary
Trial ended prematurely
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 32
1. Signed informed consent prior to any study-mandated procedure
2. Healthy male subjects, 18 to 45 years of age, inclusive.
3. Healthy volunteer part only: Body mass index (BMI) between 18 and 30 kg/m2,
inclusive and a body weight between 50 and 100 kg, inclusive at screening.
4. All male volunteers must practice effective contraception during the study
and be willing and able to continue contraception for at least 90 days after
their last dose of study treatment.
5. Has the ability to communicate well with the Investigator in the Dutch
language and willing to comply with the study restrictions.
1. Evidence (following a detailed medical history, physical examination, vital
signs, 12-lead ECG and clinical laboratory parameters) of any active or chronic
disease or condition that could interfere with, or for which the treatment
might interfere with, the conduct of the study, or that would pose an
unacceptable risk to the subject in the opinion of the investigator.
2. Clinically significant abnormalities, as judged by the investigator, in
laboratory test results (including hepatic and renal panels, complete blood
count, chemistry panel and urinalysis). Minor deviations of laboratory values
from the normal range may be accepted, if judged by the Investigator or
medically qualified designee as not clinically significant. In the case of
uncertain or questionable results, tests performed during screening may be
repeated before randomization to confirm eligibility or judged to be clinically
irrelevant for healthy subjects.
3. Positive Hepatitis B surface antigen (HBsAg), Hepatitis B antibodies,
Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV
Ab) at screening.
4. Systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and
diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg at
screening.
5. Abnormal findings in the resting ECG at screening defined as:
- QTcF> 450 or < 300 msec
- Notable resting bradycardia (HR < 45 bpm)
- Notable resting tachycardia (HR > 100 bpm)
- Personal or family history of congenital long QT syndrome or sudden death;
- ECG with QRS and/or T wave judged to be unfavorable for a consistently
accurate QT measurement (e.g., neuromuscular artefact that cannot be readily
eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T-
and U-waves, prominent U waves);
- Evidence of a sustained atrial or ventricular arrhythmia, either by anamnesis
or by Holter or telemetric observation.
- Pre-excitation (Wolff-Parkinson-White syndrome)
- PR interval >220 ms
6. Use of any medications (prescription or over-the-counter (OTC)), within 14
days of investigational product administration, or less than 5 half-lives
(whichever is longer). Exceptions are paracetamol (up to 4 g/day) and ibuprofen
(up to 1g/day). Other exceptions will only be made if the rationale is clearly
documented by the investigator.
7. Use of any vitamin, mineral, herbal, and dietary supplements within 7 days
of investigational product administration, or less than 5 half-lives (whichever
is longer). Exceptions will only be made if the rationale is clearly documented
by the investigator.
8. Participation in an investigational product or device study within 3 months
prior to first dosing, or >4 studies in the year prior to study participation.
9. History of abuse of addictive substances (alcohol, illegal substances) or
use of more than 21 units alcohol per week within 3 months prior to screening,
drug abuse, or regular user of sedatives, hypnotics, tranquillizers, or any
other addictive agent.
10. Positive test for drugs of abuse at screening or pre-dose.
11. Alcohol will not be allowed from at least 24 hours before screening or
pre-dose.
12. Routine smoker or history of nicotine abuse (average of >5 cigarettes per
day for >3 months).
13. Excess in xanthine consumption (more than eight cups of coffee
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Occurrence of all treatment-related AEs.<br /><br>• Changes in vital signs, temperature, laboratory safety data and ECGs between<br /><br>pre-first infusion and each post-infusion time point.<br /><br>• Changes in tremorography data.<br /><br>• Changes in physical examination findings.<br /><br>• Administration site reactions.</p><br>
- Secondary Outcome Measures
Name Time Method <p>• Maximum Cmax for each cohort.<br /><br>• Maximum free Cmax for each cohort.<br /><br>• Time to maximum observed plasma concentration (tmax) for each cohort.<br /><br>• AUC for each dosing group (AUC from time zero to infinity [AUCinf], AUC from<br /><br>time zero to time of last measurable concentration [AUClast], AUC from time t<br /><br>to infinity as a percentage of total AUC [AUC%extrapolated]) for each cohort.<br /><br>• Clearance (CL), volume of distribution during terminal phase (Vz) and volume<br /><br>of distribution at steady state (Vss) and half-life (t*) for each cohort.</p><br>